perphenazine has been researched along with Schizophrenia in 296 studies
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is evidence to suggest that clozapine is underutilized in treatment-refractory schizophrenia." | 9.16 | Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. ( Hermes, E; Rosenheck, R, 2012) |
| "Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1)." | 9.15 | Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. ( Addington, DE; Davis, SM; Lieberman, JA; McEvoy, JP; Mohamed, S; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011) |
| "The goal of the study was to characterize population pharmacokinetics (PPK) for perphenazine in patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)." | 9.14 | Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. ( Bies, RR; Coley, K; Florian, J; Jin, Y; Kirshner, M; Lieberman, J; Marder, SR; Miller, D; Pollock, BG; Schneider, L, 2010) |
| "Patients with schizophrenia (N=1,493) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months." | 9.12 | Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. ( Davis, SM; Hsiao, JK; Keefe, RS; Leslie, DL; Lieberman, J; Lin, H; McEvoy, J; Miller, EA; Perkins, DO; Rosenheck, RA; Sindelar, J; Stroup, TS; Swartz, M, 2006) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 9.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7." | 9.12 | Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
| " Twelve patients with schizophrenia according to RDC participated in a double-blind study, comparing two dose levels of perphenazine, 16 or 32 mg, during four weeks." | 9.06 | The relationship between perphenazine plasma levels and clinical response in acute schizophrenia. ( Bolvig-Hansen, L; Larsen, NE; Omérov, M; Wistedt, B, 1989) |
| "Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine." | 9.06 | Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989) |
| "The efficacy of timiperone in schizophrenia as compared with perphenazine was assessed in a double-blind fashion in 205 patients throughout a 12-week treatment period." | 9.05 | Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study. ( Asada, S; Inanaga, K; Nakano, S; Otsuki, S; Samejima, K; Sarai, K; Takahashi, R, 1982) |
| "To examine the clinical effects and safety of perphenazine for those with schizophrenia and schizophrenia-like psychoses." | 8.91 | Perphenazine for schizophrenia. ( Hartung, B; Leucht, S; Sampson, S, 2015) |
| "To review the effects of high-potency, first-generation perphenazine compared with low-potency, first-generation antipsychotic drugs for people with schizophrenia." | 8.90 | Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Leucht, S; Tardy, M, 2014) |
| "To assess the effects of depot perphenazine decanoate and enanthate versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes." | 8.82 | Depot perphenazine decanoate and enanthate for schizophrenia. ( David, A; Quraishi, S; Rathbone, J, 2005) |
| "We included all randomised controlled trials that compared perphenazine with other treatments for people with schizophrenia and/or schizophrenia-like psychoses." | 8.82 | Perphenazine for schizophrenia. ( Hartung, B; Laux, G; Leucht, S; Wada, M, 2005) |
| "To assess the effects of depot perphenazine decanoate and enanthate versus placebo, oral anti-psychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes." | 8.80 | Depot perphenazine decanoate and enanthate for schizophrenia. ( David, A; Quraishi, S, 2000) |
| "The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 7.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
| "Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses." | 6.79 | Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014) |
| "Patients with schizophrenia were randomized to monotherapy with risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, perphenazine or haloperidol in a 6-week pharmacological trial." | 6.23 | The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia. ( Chen, Q; Coid, J; Deng, W; Guo, W; Li, K; Li, L; Li, T; Lu, T; Lv, L; Ma, X; Tan, L; Tan, Q; Tao, S; Wang, C; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L, 2024) |
| "Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride." | 5.19 | Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. ( Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J, 2014) |
| "363 hospital-based psychiatric patients in India, Romania, and United States aged 18 to 65 years and meeting criteria for DSM-IV-TR diagnosis of chronic schizophrenia were randomized double-blind to receive BL-1020 10 mg/d, BL-1020 20-30 mg/d, placebo, or risperidone (2-8 mg/d) for 6 weeks." | 5.16 | Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. ( Anand, R; Davidson, M; Geffen, Y; Keefe, R; Rabinowitz, J, 2012) |
| " The aim of our study was to assess social cognition in schizophrenia inpatients being treated with first-generation antipsychotic drugs (FGAs), n=28 (perphenazine and haloperidol, FGAs) or with second-generation antipsychotic drugs (SGAs), n=56 (olanzapine and clozapine, SGAs)." | 5.16 | Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs. ( Czernikiewicz, A; Kucharska-Pietura, K; Mortimer, A; Tylec, A, 2012) |
| "There is evidence to suggest that clozapine is underutilized in treatment-refractory schizophrenia." | 5.16 | Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. ( Hermes, E; Rosenheck, R, 2012) |
| "Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1)." | 5.15 | Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. ( Addington, DE; Davis, SM; Lieberman, JA; McEvoy, JP; Mohamed, S; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011) |
| "The goal of the study was to characterize population pharmacokinetics (PPK) for perphenazine in patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)." | 5.14 | Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. ( Bies, RR; Coley, K; Florian, J; Jin, Y; Kirshner, M; Lieberman, J; Marder, SR; Miller, D; Pollock, BG; Schneider, L, 2010) |
| " The goal of this randomized, double-blind study is to compare the effects of several second generation antipsychotics and a first generation antipsychotic, perphenazine, on emotion perception in individuals with schizophrenia." | 5.14 | The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. ( Davis, SM; Keefe, RS; Lieberman, JA; Losardo, D; Meyer, PS; Penn, DL; Perkins, DO, 2009) |
| "Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment." | 5.13 | The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. ( Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR, 2008) |
| "Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al." | 5.12 | Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. ( Bilder, RM; Capuano, G; Davis, CE; Davis, SM; Gold, JM; Green, MF; Harvey, PD; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Palmer, BW; Perkins, DO; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 5.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7." | 5.12 | Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
| "Patients with schizophrenia (N=1,493) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months." | 5.12 | Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. ( Davis, SM; Hsiao, JK; Keefe, RS; Leslie, DL; Lieberman, J; Lin, H; McEvoy, J; Miller, EA; Perkins, DO; Rosenheck, RA; Sindelar, J; Stroup, TS; Swartz, M, 2006) |
| "The objective of this study was to report the effect of the slow withdrawal of clozapine from 19 patients with neuroleptic-responsive schizophrenia at the end of a 2-year clinical trial of clozapine and to compare this with the results of naturalistic discontinuation of clozapine treatment in 64 neuroleptic-resistant schizophrenic patients." | 5.08 | Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. ( Cola, PA; Lee, MA; Mason, EA; Meltzer, HY; Ranjan, R, 1996) |
| " The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol." | 5.07 | Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients. ( Aizenberg, D; Hermesh, H; Lapidot, M; Mayor, C; Munitz, H; Weizman, A, 1992) |
| " Twelve patients with schizophrenia according to RDC participated in a double-blind study, comparing two dose levels of perphenazine, 16 or 32 mg, during four weeks." | 5.06 | The relationship between perphenazine plasma levels and clinical response in acute schizophrenia. ( Bolvig-Hansen, L; Larsen, NE; Omérov, M; Wistedt, B, 1989) |
| "Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine." | 5.06 | Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989) |
| "The efficacy of timiperone in schizophrenia as compared with perphenazine was assessed in a double-blind fashion in 205 patients throughout a 12-week treatment period." | 5.05 | Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study. ( Asada, S; Inanaga, K; Nakano, S; Otsuki, S; Samejima, K; Sarai, K; Takahashi, R, 1982) |
| "To examine the clinical effects and safety of perphenazine for those with schizophrenia and schizophrenia-like psychoses." | 4.91 | Perphenazine for schizophrenia. ( Hartung, B; Leucht, S; Sampson, S, 2015) |
| "To review the effects of high-potency, first-generation perphenazine compared with low-potency, first-generation antipsychotic drugs for people with schizophrenia." | 4.90 | Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Leucht, S; Tardy, M, 2014) |
| "To assess the effects of depot perphenazine decanoate and enanthate versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes." | 4.82 | Depot perphenazine decanoate and enanthate for schizophrenia. ( David, A; Quraishi, S; Rathbone, J, 2005) |
| "We included all randomised controlled trials that compared perphenazine with other treatments for people with schizophrenia and/or schizophrenia-like psychoses." | 4.82 | Perphenazine for schizophrenia. ( Hartung, B; Laux, G; Leucht, S; Wada, M, 2005) |
| "To assess the effects of depot perphenazine decanoate and enanthate versus placebo, oral anti-psychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes." | 4.80 | Depot perphenazine decanoate and enanthate for schizophrenia. ( David, A; Quraishi, S, 2000) |
| "The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 3.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
| "The objective of this study was to evaluate the impact of once- versus twice-daily dosing of perphenazine, which has a plasma half-life of 8-12 hours, on clinical outcomes in patients with schizophrenia." | 3.80 | Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. ( Bies, RR; Fervaha, G; Grönte, D; Remington, G; Suzuki, T; Takeuchi, H; Uchida, H, 2014) |
| "One hundred and sixty-three first-episode inpatients with schizophrenia were recruited, to whom one of three conventional antipsychotics (perphenazine, sulpiride, and chlorpromazine) or one of three atypical antipsychotics (clozapine, quetiapine, and aripiprazole) was prescribed for 12 months as appropriate." | 3.80 | Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. ( Cao, B; Hou, R; Jian, J; Mi, G; Qiu, H; Tang, M; Wang, M, 2014) |
| " We measured the all-cause mortality of patients with schizophrenia in outpatient care during current and cumulative exposure to any antipsychotic drug versus no use of these drugs, and exposure to the six most frequently used antipsychotic drugs compared with perphenazine use." | 3.75 | 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). ( Haukka, J; Klaukka, T; Lönnqvist, J; Niskanen, L; Tanskanen, A; Tiihonen, J; Wahlbeck, K, 2009) |
| "The advantages of BL-1020 for treatment of schizophrenia stem from its being a DA/5HT antagonist and a GABAergic agonist that releases cortical DA and antagonizes amphetamine-induced hyperactivity with reduced catalepsy and sedation." | 3.75 | BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ( Geffen, Y; Gil-Ad, I; Huang, M; Klapper, L; Meltzer, HY; Nudelman, A; Rephaeli, A; Savitsky, K; Weizman, A; Winkler, I, 2009) |
| "Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses." | 2.79 | Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014) |
| "Schizophrenia is an often devastating neuropsychiatric illness." | 2.76 | Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. ( Aberg, K; Adkins, DE; Lieberman, JA; McClay, JL; Perkins, DO; Stroup, S; Sullivan, PF; van den Oord, EJ; Vladimirov, VI, 2011) |
| "Treatment with perphenazine was more effective than treatment with quetiapine (p = ." | 2.73 | Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. ( Campbell, DB; Ebert, PJ; Levitt, P; Lieberman, J; Skelly, T; Stroup, TS; Sullivan, PF, 2008) |
| " Dopaminergic and serotonergic pathways are involved in the therapeutic and adverse effects of the drug." | 2.73 | Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. ( Dahl, ML; Gunes, A; Jaanson, P; Scordo, MG, 2007) |
| "Perphenazine was not significantly different in overall effectiveness, compared with quetiapine, risperidone, and ziprasidone." | 2.73 | What CATIE found: results from the schizophrenia trial. ( Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Rosenheck, RA; Stroup, TS; Swartz, MS, 2008) |
| "Risperidone was compared in 2 double blind studies with haloperidol and perphenazine in schizophrenic psychoses." | 2.68 | [Efficacy and tolerance of risperidone in various doses (report of a study)]. ( Cesková, E; Svestka, J, 1996) |
| "Perphenazine level was not correlated with EPS; but benztropine, given only if required for serious EPS, was more likely to be used when perphenazine levels were elevated." | 2.67 | The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. ( Bowers, MB; Jatlow, PI; Kincare, P; Mazure, CM; Nelson, JC, 1990) |
| "The purpose of the study was to investigate clinical and pharmacokinetic parameters concerning perphenazine decanoate (PD) and haloperidol decanoate (HD) with an interval of 3 weeks during a study period of 51 weeks." | 2.67 | A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. ( Dencker, SJ; Giös, I; Mårtensson, E; Nordén, T; Nyberg, G; Persson, R; Roman, G; Stockman, O; Svärd, KO, 1994) |
| " This study demonstrates that PD is a safe and effective remedy for maintenance therapy in psychotic patients." | 2.66 | Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. ( Hansen, LB; Højholdt, K; Knudsen, P; Larsen, NE, 1985) |
| " In the patients treated with PD there were signs of accumulation indicating the possibility of prolonging dosage intervals." | 2.66 | Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. ( Auken, G; Hansen, LB; Højholdt, K; Knudsen, P; Larsen, NE; Waehrens, J, 1985) |
| "Biperiden treatment did not influence the effect of PE on the PRL levels." | 2.64 | Effects of perphenazine enanthate injections on prolactin levels in plasma from schizophrenic women and men. ( Gullberg, B; Lindholm, H; Ohman, A; Sedvall, G, 1978) |
| " Improvement was recorded in a double blind study of 18 patients treated with maximum tolerated dosage (mean 18." | 2.64 | Tardive dyskinesia treated with pimozide. ( Calne, DB; Claveria, LE; Haskayne, L; Lodge-Patch, IC; Pallis, CA; Petrie, A; Teychenne, PF, 1975) |
| " The employed dosage caused no strong sedation." | 2.64 | Double-blind comparison of bromperidol and perphenazine. ( Angst, J; Woggon, B, 1978) |
| " The daily dosage varied from 300 to 1,200 mg Sulpiride orally and 12 to 48 mg Perphenazine." | 2.64 | [Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double blind method]. ( Asada, S; Ishimaru, T; Kodama, H; Kubo, S; Masuda, K, 1976) |
| "Amitriptyline alone was not substantially better than placebo and could not be considered an efficacious medication for the maintenance treatment of these patients." | 2.64 | Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controled study of drug interaction. ( Albert, JM; Annable, L; Charette, R; Chouinard, G; Serrano, M, 1975) |
| "Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone." | 2.58 | Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. ( Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T, 2018) |
| "Among the 15 most widely used antipsychotics, 13 had a U- or J-shaped dose-response curve, showing the lowest risks of relapse for doses of 0." | 1.72 | Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. ( Correll, CU; Leucht, S; Luykx, JJ; Solmi, M; Taipale, H; Tanskanen, A; Tiihonen, J, 2022) |
| "Acute dystonia is a common adverse effect following anti-psychotic medication, which mainly appears shortly after beginning treatment or increasing the dosage." | 1.30 | [Atypical acute dystonia]. ( Mors, NP; Nielsen, AS, 1998) |
| "A case of perphenazine-induced aplastic anemia in a 23-year-old schizophrenic man is reported." | 1.30 | Acquired aplastic anemia secondary to perphenazine. ( Oyewumi, LK, 1999) |
| "Perphenazine levels were more variable (46%) than haloperidol (25%) and flupenthixol (12." | 1.29 | Large variations of plasma levels during maintenance treatment with depot neuroleptics. ( Levander, S; Tuninger, E, 1996) |
| "The fulminant pulmonary edema in the three cases resolved within 18 to 40 h." | 1.28 | Acute pulmonary edema induced by overdosage of phenothiazines. ( Gefter, WB; Li, C, 1992) |
| " Moreover pharmacokinetic data increasingly have been clinically applied." | 1.27 | Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. ( Knudsen, P, 1985) |
| " The dosage and intervals between injections were on an individual basis." | 1.27 | Perphenazine decanoate in sesame oil vs. perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications. ( Hansen, LB; Knudsen, P; Larsen, NE, 1985) |
| "The determinants of relapse have been elusive." | 1.26 | Low serum neuroleptic levels predict relapse in schizophrenic patients. ( Brown, WA; Chisholm, E; Laughren, T; Williams, BW, 1982) |
| "These episodes are differentiated from nocturnal wanderings and epileptic attacks during sleep; they occurred within two to three hours after sleep onset and were characterized by the patients appearing confused and walking about in a quiet, detached and clumsy manner." | 1.26 | Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment. ( Charney, DS; Kales, A; Nelson, JC; Soldatos, CR, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 175 (59.12) | 18.7374 |
| 1990's | 35 (11.82) | 18.2507 |
| 2000's | 45 (15.20) | 29.6817 |
| 2010's | 38 (12.84) | 24.3611 |
| 2020's | 3 (1.01) | 2.80 |
| Authors | Studies |
|---|---|
| Nudelman, A | 2 |
| Gil-Ad, I | 2 |
| Shpaisman, N | 1 |
| Terasenko, I | 1 |
| Ron, H | 1 |
| Savitsky, K | 2 |
| Geffen, Y | 3 |
| Weizman, A | 5 |
| Rephaeli, A | 2 |
| Taipale, H | 2 |
| Tanskanen, A | 3 |
| Luykx, JJ | 1 |
| Solmi, M | 1 |
| Leucht, S | 4 |
| Correll, CU | 4 |
| Tiihonen, J | 3 |
| Zhang, Y | 1 |
| Tao, S | 1 |
| Coid, J | 1 |
| Wei, W | 1 |
| Wang, Q | 1 |
| Yue, W | 1 |
| Yan, H | 1 |
| Tan, L | 1 |
| Chen, Q | 1 |
| Yang, G | 1 |
| Lu, T | 1 |
| Wang, L | 1 |
| Zhang, F | 1 |
| Yang, J | 1 |
| Li, K | 1 |
| Lv, L | 1 |
| Tan, Q | 1 |
| Zhang, H | 1 |
| Ma, X | 2 |
| Yang, F | 1 |
| Li, L | 1 |
| Wang, C | 1 |
| Zhao, L | 1 |
| Deng, W | 1 |
| Guo, W | 1 |
| Zhang, D | 1 |
| Li, T | 1 |
| Pathak, S | 1 |
| Jiang, Y | 1 |
| DiPetrillo, L | 1 |
| Todtenkopf, MS | 1 |
| Liu, Y | 1 |
| Beresford, T | 1 |
| Buchanan, J | 1 |
| Thumm, EB | 1 |
| Emrick, C | 1 |
| Weitzenkamp, D | 1 |
| Ronan, PJ | 1 |
| Mehtälä, J | 1 |
| Temmingh, HS | 1 |
| Williams, T | 1 |
| Siegfried, N | 1 |
| Stein, DJ | 1 |
| Hendouei, N | 1 |
| Farnia, S | 1 |
| Mohseni, F | 1 |
| Salehi, A | 1 |
| Bagheri, M | 1 |
| Shadfar, F | 1 |
| Barzegar, F | 1 |
| Hoseini, SD | 1 |
| Charati, JY | 1 |
| Shaki, F | 1 |
| McCain, CF | 1 |
| Namey, LB | 1 |
| Freudenreich, O | 1 |
| Bellavia, A | 1 |
| Centorrino, F | 1 |
| Jackson, JW | 1 |
| Fitzmaurice, G | 1 |
| Valeri, L | 1 |
| Bareis, N | 1 |
| Stroup, TS | 16 |
| Arnold, JG | 1 |
| Miller, AL | 3 |
| Cañive, JM | 3 |
| Rosenheck, RA | 13 |
| Swartz, MS | 12 |
| Mintz, J | 1 |
| Berle, JØ | 1 |
| Løberg, EM | 1 |
| Fasmer, OB | 1 |
| Volavka, J | 1 |
| Czobor, P | 1 |
| Citrome, L | 2 |
| Van Dorn, RA | 1 |
| Fischer, BA | 1 |
| Rosenheck, R | 3 |
| Lin, H | 3 |
| Takeuchi, H | 1 |
| Fervaha, G | 1 |
| Uchida, H | 1 |
| Suzuki, T | 1 |
| Bies, RR | 2 |
| Grönte, D | 1 |
| Remington, G | 1 |
| Wang, M | 1 |
| Hou, R | 1 |
| Jian, J | 1 |
| Mi, G | 1 |
| Qiu, H | 1 |
| Cao, B | 1 |
| Tang, M | 1 |
| Tardy, M | 1 |
| Huhn, M | 1 |
| Engel, RR | 1 |
| Ramsey, TL | 1 |
| Brennan, MD | 1 |
| Hartung, B | 2 |
| Sampson, S | 1 |
| Mohamed, S | 2 |
| Swartz, M | 4 |
| McEvoy, J | 3 |
| Stroup, S | 2 |
| Melkersson, K | 1 |
| Lewitt, M | 1 |
| Hall, K | 1 |
| Kim, E | 1 |
| Mao, L | 1 |
| Starr, HL | 1 |
| Alphs, L | 1 |
| Meyer, JM | 1 |
| Davis, VG | 2 |
| McEvoy, JP | 10 |
| Goff, DC | 1 |
| Nasrallah, HA | 2 |
| Davis, SM | 12 |
| Daumit, GL | 1 |
| Hsiao, J | 1 |
| Lieberman, JA | 16 |
| Fusar-Poli, RR | 1 |
| Huang, M | 1 |
| Klapper, L | 1 |
| Winkler, I | 1 |
| Meltzer, HY | 4 |
| Keefe, RS | 10 |
| Hsiao, JK | 9 |
| Lönnqvist, J | 1 |
| Wahlbeck, K | 1 |
| Klaukka, T | 1 |
| Niskanen, L | 1 |
| Haukka, J | 1 |
| McClay, JL | 1 |
| Adkins, DE | 1 |
| Aberg, K | 1 |
| Perkins, DO | 6 |
| Vladimirov, VI | 1 |
| Sullivan, PF | 2 |
| van den Oord, EJ | 1 |
| Penn, DL | 1 |
| Meyer, PS | 1 |
| Losardo, D | 1 |
| Kraemer, HC | 1 |
| Glick, ID | 3 |
| Klein, DF | 1 |
| Jin, Y | 1 |
| Pollock, BG | 1 |
| Coley, K | 1 |
| Miller, D | 2 |
| Marder, SR | 2 |
| Florian, J | 1 |
| Schneider, L | 1 |
| Lieberman, J | 4 |
| Kirshner, M | 1 |
| Fitzgerald, PB | 1 |
| De Hert, M | 1 |
| Cohen, D | 1 |
| Novick, D | 1 |
| Ascher-Svanum, H | 2 |
| Zhu, B | 2 |
| Brnabic, A | 1 |
| Stauffer, V | 1 |
| Peng, X | 1 |
| Karagianis, J | 1 |
| Perrin, E | 1 |
| Caroff, SN | 1 |
| Miller, DD | 2 |
| Campbell, EC | 1 |
| Saltz, BL | 1 |
| Riggio, S | 1 |
| Chakos, MH | 1 |
| Addington, DE | 1 |
| Abbott, A | 1 |
| Yolken, RH | 1 |
| Torrey, EF | 1 |
| Yang, S | 1 |
| Dickerson, FB | 1 |
| Yoon, FB | 1 |
| Fitzmaurice, GM | 1 |
| Lipsitz, SR | 1 |
| Horton, NJ | 1 |
| Laird, NM | 1 |
| Normand, SL | 1 |
| Chakos, M | 1 |
| Patel, JK | 1 |
| Hammer, MB | 1 |
| Tapp, A | 1 |
| Miller, A | 1 |
| Zedkova, I | 1 |
| Dudova, I | 1 |
| Urbanek, T | 1 |
| Hrdlicka, M | 1 |
| Kucharska-Pietura, K | 2 |
| Tylec, A | 2 |
| Czernikiewicz, A | 2 |
| Mortimer, A | 2 |
| Koranek, AM | 1 |
| Smith, TL | 1 |
| Mican, LM | 1 |
| Rascati, KL | 1 |
| Hermes, E | 1 |
| Keefe, R | 1 |
| Rabinowitz, J | 1 |
| Anand, R | 1 |
| Davidson, M | 1 |
| GREGORETTI, L | 1 |
| NAHUNEK, K | 22 |
| RODOVA, A | 13 |
| CASEY, JF | 1 |
| LASKY, JJ | 1 |
| KLETT, CJ | 1 |
| HOLLISTER, LE | 5 |
| GERZ, HO | 1 |
| OLTMAN, JE | 3 |
| FRIEDMAN, S | 3 |
| GALENKO, VE | 1 |
| KUZNETSOV, ON | 2 |
| SOULAIRAC, A | 1 |
| GEIER, S | 1 |
| MOREL, P | 1 |
| FILLIOZAT, AM | 1 |
| FILLIOZAT, R | 1 |
| CHAVANNES, N | 1 |
| WHITTAKER, CB | 1 |
| HOY, RM | 1 |
| YAMAUCHI, I | 1 |
| COOPER, TB | 4 |
| CRANSWICK, EH | 3 |
| KENNEDY, RE | 1 |
| MILLER, JJ | 1 |
| KARACAN, I | 1 |
| JONES, F | 1 |
| ERSEVIM, I | 1 |
| CHAPPLE, ED | 2 |
| CHAMBERLAIN, A | 1 |
| ESSER, AH | 2 |
| KLINE, NS | 2 |
| SIMPSON, GM | 7 |
| ERNST, EM | 1 |
| AMUSO, D | 1 |
| BLAIR, JH | 2 |
| FARKAS, T | 1 |
| OVERALL, JE | 3 |
| MEYER, F | 1 |
| SHELTON, J | 2 |
| MARKS, J | 1 |
| SUGERMAN, AA | 2 |
| GOLDSTEIN, L | 3 |
| MURPHREE, HB | 3 |
| PFEIFFER, CC | 3 |
| JENNEY, EH | 2 |
| HACHIYA, H | 1 |
| ILLBERG, P | 1 |
| FINN, R | 1 |
| JENKINS, SB | 1 |
| SAMBORSKI, AH | 1 |
| SHARPLEY, P | 1 |
| HEISTAD, G | 1 |
| SCHIELE, BC | 2 |
| WATANABE, A | 1 |
| YOSHIMOTO, K | 1 |
| FORREST, FM | 1 |
| GEITER, CW | 1 |
| SNOW, HL | 1 |
| STEINBACH, M | 1 |
| HUANG, CL | 1 |
| KURLAND, AA | 1 |
| HARDI, I | 1 |
| COHEN, S | 1 |
| LEONARD, CV | 1 |
| FARBEROW, NL | 1 |
| SHNEIDMAN, ES | 1 |
| KRAKOWSKI, AJ | 1 |
| MORI, A | 1 |
| YABUKI, Y | 1 |
| LLOYD, DN | 1 |
| NEWBROUGH, JR | 1 |
| Faurbye, A | 1 |
| Clausen, J | 1 |
| PETERSEN, PB | 1 |
| RASCH, PJ | 1 |
| LOWY, F | 1 |
| FLEISCHL, H | 1 |
| HARTMAN, BJ | 1 |
| CHAMBERLAIN, AS | 1 |
| ITIL, TM | 1 |
| BAN, TA | 5 |
| LEHMANN, HE | 3 |
| CHEN, CH | 1 |
| HOLSTEIN, AP | 1 |
| PRASAD, PS | 1 |
| GANTZ, RS | 1 |
| BIRKETT, DP | 1 |
| BONINO, D | 1 |
| GAMNA, G | 1 |
| PLAVEC, J | 1 |
| SCHRAMM, LP | 1 |
| HARAN, T | 1 |
| Talvik, M | 1 |
| Nordström, AL | 1 |
| Larsen, NE | 10 |
| Jucaite, A | 1 |
| Cervenka, S | 1 |
| Halldin, C | 1 |
| Farde, L | 1 |
| Wada, M | 1 |
| Laux, G | 1 |
| David, A | 2 |
| Quraishi, S | 2 |
| Rathbone, J | 1 |
| Davis, CE | 2 |
| Lebowitz, BD | 1 |
| Severe, J | 1 |
| Andersen, TH | 1 |
| Bech, P | 1 |
| Delisi, LE | 1 |
| Luchins, DJ | 1 |
| Pandiani, JA | 1 |
| Banks, SM | 1 |
| Dettling, M | 1 |
| Anghelescu, IG | 1 |
| Gupta, N | 1 |
| Basu, D | 1 |
| Faries, D | 1 |
| Landbloom, R | 1 |
| Swanson, J | 1 |
| Haddad, P | 1 |
| Dursun, SM | 1 |
| Shkedy, Z | 1 |
| Schreiner, A | 1 |
| Gunes, A | 1 |
| Scordo, MG | 1 |
| Jaanson, P | 1 |
| Dahl, ML | 2 |
| Leslie, DL | 1 |
| Sindelar, J | 1 |
| Miller, EA | 1 |
| Capuano, G | 2 |
| Reimherr, F | 2 |
| McGee, MF | 1 |
| Capuano, GA | 1 |
| Belz, I | 1 |
| Soumerai, SB | 1 |
| Law, MR | 1 |
| Strassnig, M | 1 |
| Miewald, J | 1 |
| Keshavan, M | 1 |
| Ganguli, R | 1 |
| Bilder, RM | 1 |
| Harvey, PD | 1 |
| Palmer, BW | 1 |
| Gold, JM | 1 |
| Green, MF | 1 |
| Campbell, DB | 1 |
| Ebert, PJ | 1 |
| Skelly, T | 1 |
| Levitt, P | 1 |
| Bick, P | 1 |
| Knoesen, N | 1 |
| Castle, D | 1 |
| Wagner, HR | 1 |
| Swanson, JW | 1 |
| McGee, M | 1 |
| Khan, A | 1 |
| Resnick, SG | 1 |
| De Souza, C | 1 |
| Davis, S | 1 |
| Jaffe, A | 1 |
| Martello, D | 1 |
| Allingham, B | 1 |
| Levine, J | 2 |
| Jaquith, WL | 1 |
| Nail, HR | 1 |
| Smith, BS | 1 |
| Taylor, MR | 1 |
| Svestka, J | 20 |
| Cesková, E | 11 |
| Bochkarev, VK | 1 |
| Paniushkina, SV | 1 |
| Brown, WA | 1 |
| Laughren, T | 1 |
| Chisholm, E | 1 |
| Williams, BW | 1 |
| Takahashi, R | 2 |
| Inanaga, K | 1 |
| Samejima, K | 1 |
| Sarai, K | 1 |
| Asada, S | 2 |
| Otsuki, S | 1 |
| Nakano, S | 1 |
| Hertrich, O | 1 |
| Ahlfors, UG | 1 |
| Dencker, SJ | 2 |
| Gravem, A | 1 |
| Remvig, J | 3 |
| Levick, SE | 1 |
| Jalali, B | 1 |
| Strauss, JS | 1 |
| Lowental, U | 1 |
| Høyberg, OJ | 1 |
| Fensbo, C | 1 |
| Lingjaerde, O | 1 |
| Sloth-Nielsen, M | 1 |
| Salvesen, I | 1 |
| Rothschild, AJ | 1 |
| Knecht, T | 1 |
| Giös, I | 1 |
| Mårtensson, E | 1 |
| Nordén, T | 1 |
| Nyberg, G | 1 |
| Persson, R | 1 |
| Roman, G | 1 |
| Stockman, O | 1 |
| Svärd, KO | 1 |
| Spigset, O | 1 |
| Carleborg, L | 1 |
| Mjörndal, T | 1 |
| Norström, A | 1 |
| Sundgren, M | 1 |
| Spivak, B | 1 |
| Kosower, N | 1 |
| Zipser, Y | 1 |
| Shreiber-Schul, N | 1 |
| Apter, A | 1 |
| Tyano, S | 1 |
| Larsen, EB | 1 |
| Gerlach, J | 3 |
| Maes, M | 1 |
| De Meester, I | 1 |
| Scharpe, S | 1 |
| Desnyder, R | 1 |
| Ranjan, R | 2 |
| Tuninger, E | 2 |
| Levander, S | 2 |
| Peacock, L | 1 |
| Solgaard, T | 1 |
| Lublin, H | 1 |
| Lee, MA | 1 |
| Mason, EA | 1 |
| Cola, PA | 1 |
| Caspi, N | 1 |
| Laufer, N | 1 |
| Ryding, E | 1 |
| Ohlsson, T | 1 |
| Sjöholm, H | 1 |
| Freccero-Rosman, K | 1 |
| Rosén, I | 1 |
| Canuso, CM | 1 |
| Hanau, M | 1 |
| Jhamb, KK | 1 |
| Green, AI | 1 |
| Nielsen, AS | 1 |
| Mors, NP | 1 |
| Rafal, S | 1 |
| Tsuang, MT | 1 |
| Carpenter, WT | 1 |
| Oyewumi, LK | 1 |
| Hermesh, H | 3 |
| Manor, I | 1 |
| Munitz, H | 3 |
| Reznik, I | 1 |
| Sirota, P | 1 |
| Shiloh, R | 1 |
| Weizer, N | 1 |
| Dorfman-Etrog, P | 1 |
| Gaertner, I | 1 |
| Altendorf, K | 1 |
| Batra, A | 1 |
| Gaertner, HJ | 1 |
| Drybcák, P | 1 |
| Hrobar, P | 1 |
| Lorenc, M | 1 |
| Spacek, J | 1 |
| Hong, X | 1 |
| Wang, X | 1 |
| Ketai, R | 1 |
| Davis, JM | 2 |
| Gosenfeld, L | 1 |
| Tsai, CC | 1 |
| Charney, DS | 1 |
| Kales, A | 1 |
| Soldatos, CR | 1 |
| Nelson, JC | 6 |
| Lindholm, H | 1 |
| Gullberg, B | 1 |
| Ohman, A | 1 |
| Sedvall, G | 1 |
| Langer, G | 2 |
| Sachar, EJ | 2 |
| Nathan, RS | 1 |
| Tabrizi, MA | 1 |
| Perel, JM | 1 |
| Halpern, FS | 2 |
| Gruen, PH | 1 |
| Claveria, LE | 1 |
| Teychenne, PF | 1 |
| Calne, DB | 1 |
| Haskayne, L | 1 |
| Petrie, A | 1 |
| Pallis, CA | 1 |
| Lodge-Patch, IC | 1 |
| Obukhov, GA | 1 |
| Chouinard, G | 2 |
| Annable, L | 2 |
| Woggon, B | 2 |
| Angst, J | 2 |
| Prusoff, BA | 2 |
| Williams, DH | 2 |
| Weissman, MM | 2 |
| Astrachan, BM | 2 |
| Eufe, R | 1 |
| Wegener, G | 1 |
| Cooper, SF | 1 |
| Dugal, R | 2 |
| Elie, R | 2 |
| Albert, JM | 3 |
| Korsgaard, S | 1 |
| Skausig, OB | 1 |
| Tegeler, J | 1 |
| Floru, L | 1 |
| Cooper, S | 1 |
| Bertrand, M | 1 |
| Gold, MS | 1 |
| Sweeney, DR | 1 |
| Storrie, MC | 1 |
| Scher, M | 1 |
| McGuire, J | 1 |
| Bokan, J | 1 |
| Ishimaru, T | 1 |
| Kubo, S | 1 |
| Kodama, H | 1 |
| Masuda, K | 1 |
| Serrano, M | 1 |
| Charette, R | 1 |
| Swett, C | 1 |
| Hersen, M | 1 |
| Turner, SM | 1 |
| Edelstein, BA | 1 |
| Pinkston, SG | 1 |
| Gram, LF | 2 |
| Feng, ZY | 1 |
| Aizenberg, D | 1 |
| Lapidot, M | 1 |
| Mayor, C | 1 |
| Bowers, MB | 5 |
| Mazure, CM | 5 |
| Jatlow, PI | 5 |
| Warkentin, S | 1 |
| Nilsson, A | 1 |
| Karlson, S | 1 |
| Risberg, J | 1 |
| Franze'n, G | 1 |
| Gustafson, L | 1 |
| Van Putten, T | 1 |
| Wirshing, WC | 1 |
| Aravagiri, M | 1 |
| Chabert, N | 1 |
| Li, C | 1 |
| Gefter, WB | 1 |
| Kistrup, K | 1 |
| Aaes-Jørgensen, T | 1 |
| Gerken, A | 1 |
| Wetzel, H | 1 |
| Benkert, O | 1 |
| Ekqvist, B | 1 |
| Widén, J | 1 |
| Bertilsson, L | 1 |
| Wetterberg, L | 1 |
| Kincare, P | 1 |
| Rysánek, R | 5 |
| Lewis, DG | 1 |
| Balsíková, J | 1 |
| Omérov, M | 1 |
| Wistedt, B | 1 |
| Bolvig-Hansen, L | 1 |
| Lepola, U | 1 |
| Koskinen, T | 1 |
| Rimón, R | 1 |
| Salo, H | 1 |
| Gordin, A | 1 |
| Curry, SH | 1 |
| Knudsen, P | 6 |
| Harrop, DS | 1 |
| Galdi, J | 1 |
| Bonato, RR | 1 |
| Olfson, M | 1 |
| Hansen, LB | 6 |
| Auken, G | 1 |
| Waehrens, J | 1 |
| Højholdt, K | 3 |
| Fabius, AJ | 1 |
| Gaulhofer, WK | 1 |
| Kimbell, I | 2 |
| Pokorny, A | 1 |
| Snyder, S | 1 |
| Greenberg, D | 2 |
| Yamamura, HI | 1 |
| Avrutskii, GIa | 1 |
| Gurovich, IIa | 1 |
| Prokhorova, IS | 1 |
| Tirkel'taub, IuA | 1 |
| Romanov, IuD | 1 |
| Snyder, SH | 1 |
| Yamumura, HI | 1 |
| Hansen, JM | 1 |
| Siersbaek-Nielsen, K | 1 |
| St Jean, A | 1 |
| Sterlin, C | 2 |
| Noe, W | 1 |
| Petrova, ES | 1 |
| Stille, G | 1 |
| Prien, RF | 1 |
| Gillis, RD | 1 |
| Caffey, EM | 1 |
| Aarkrog, T | 1 |
| Vinar, O | 1 |
| Stika, L | 1 |
| Haaszová, M | 1 |
| Overo, K | 1 |
| Kirk, L | 1 |
| Collins, AD | 1 |
| Dundas, J | 1 |
| Affleck, JW | 1 |
| Cooper, AJ | 1 |
| Forrest, AD | 1 |
| Smythies, JR | 1 |
| Zealley, AK | 1 |
| Misurec, J | 2 |
| Hádlík, J | 3 |
| Vanýsek, J | 2 |
| Kingstone, E | 1 |
| Kolivakis, T | 1 |
| Kossatz, I | 1 |
| Krakov, L | 1 |
| Kunz-Bartholini, E | 1 |
| Becker, RE | 1 |
| Fracchia, J | 1 |
| Sheppard, C | 1 |
| Merlis, S | 2 |
| Kellam, AM | 1 |
| Jones, KS | 1 |
| Rappaport, M | 2 |
| St-Jean, A | 1 |
| Scott, J | 1 |
| Bartolucci, G | 1 |
| Lee, H | 1 |
| Dehnel, LL | 1 |
| Vestre, ND | 1 |
| Arbitman, R | 1 |
| Yurtcu, A | 1 |
| Jarrold, L | 1 |
| Gundersen, HJ | 1 |
| Amdisen, A | 1 |
| Krystof, J | 1 |
| Zyg, J | 1 |
| Mitkiewicz, S | 1 |
| Kaczyński, J | 1 |
| Villeneuve, A | 1 |
| el-Yosef, MK | 1 |
| Janowsky, DS | 1 |
| Sekerke, HJ | 1 |
| Uno, M | 1 |
| Invernizzi, G | 1 |
| Sostero, M | 1 |
| Vitali, A | 1 |
| Campanella, F | 1 |
| Madsen, A | 1 |
| Sorensen, J | 1 |
| Petersson, H | 1 |
| Sorensen, B | 1 |
| Kristjansen, P | 1 |
| Akimoto, H | 1 |
| Shimazaki, T | 1 |
| Shibata, N | 1 |
| Sato, Y | 1 |
| Radzuweit, H | 1 |
| Knorr, W | 1 |
| Yaryura-Tobias, JA | 1 |
| Wolpert, A | 1 |
| Dana, L | 1 |
| Knowles, M | 1 |
| Saunders, M | 1 |
| McClelland, HA | 1 |
| Kampman, R | 1 |
| Leppäluoto, V | 1 |
| Perlson, P | 1 |
| Tobin, JM | 1 |
| Moore, MT | 1 |
| Book, MH | 1 |
| Schipper, JA | 1 |
| Altshuler, KZ | 1 |
| Deming, WE | 1 |
| Proctor, CD | 1 |
| Cho, JB | 1 |
| Ashley, LG | 1 |
| Potts, JL | 1 |
| Eaton, HE | 1 |
| McGriff, JE | 1 |
| Douglas, JG | 1 |
| Amoroso, CP | 1 |
| Smulevich, AB | 1 |
| Golovan', LI | 1 |
| Sokolova, ED | 1 |
| Tsutsul'kovskaia, MIa | 1 |
| Rapp, W | 1 |
| Brophy, JJ | 1 |
| Fann, WE | 1 |
| Ekdawi, MY | 1 |
| Fowke, R | 1 |
| Dorfman, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial[NCT02639702] | Phase 4 | 30 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | ||
| A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia[NCT02918825] | 100 participants (Actual) | Interventional | 2016-09-01 | Completed | |||
| "Is the Use of High Intensity Interval Training (HIIT) Feasible and Acceptable Amongst Inpatients With Severe Mental Illness (SMI)? A Pilot Study"[NCT03959735] | 19 participants (Actual) | Interventional | 2019-10-10 | Completed | |||
| Person-Centered Psychosis Care: An Educational Intervention for Inpatient Staff[NCT03182283] | 100 participants (Actual) | Interventional | 2014-04-25 | Completed | |||
| Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response[NCT03495024] | Phase 4 | 10 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| A Double Blind Placebo Controlled Study of Valaciclovir in Treatment of Psychosis in Patients With Schizophrenia[NCT01364792] | Phase 2 | 24 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone[NCT00567710] | Phase 2 | 360 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| Relative Effectiveness of Schizophrenia Therapy (REST) Study[NCT01245348] | 1,110 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain[NCT05001399] | 60 participants (Actual) | Interventional | 2021-10-25 | Completed | |||
| Clinical Utility of Pharmacogenomics of Psychotropic Medications[NCT03907124] | Phase 4 | 0 participants (Actual) | Interventional | 2019-06-03 | Withdrawn (stopped due to PI left institution prior to recruitment.) | ||
| A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia[NCT01623713] | Phase 2 | 260 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis[NCT04368039] | 20 participants (Anticipated) | Interventional | 2019-12-04 | Recruiting | |||
| E-SMART: Examining Strategy Monitoring and Remediation Training for Schizophrenia[NCT04756388] | 90 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | |||
| Virtual Cognitive Behavioural Therapy for Psychosis: A Randomized Controlled Trial[NCT04752449] | 60 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | |||
| Effects of Adding Transcranial Direct Current Stimulation to Executive Function Training for Schizophrenia-spectrum Disorders - a Randomized Control Trial[NCT05389345] | 40 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | |||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
12 reviews available for perphenazine and Schizophrenia
| Article | Year |
|---|---|
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disor | 2018 |
Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.
Topics: Adult; Antipsychotic Agents; Humans; Perphenazine; Randomized Controlled Trials as Topic; Schizophre | 2014 |
Perphenazine for schizophrenia.
Topics: Antipsychotic Agents; Humans; Mental Disorders; Perphenazine; Randomized Controlled Trials as Topic; | 2015 |
Clinical trials design lessons from the CATIE study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Dru | 2009 |
BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic | 2010 |
Perphenazine for schizophrenia.
Topics: Antipsychotic Agents; Humans; Mental Disorders; Perphenazine; Randomized Controlled Trials as Topic; | 2005 |
Depot perphenazine decanoate and enanthate for schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Perphenazine; Randomized Controlled Trial | 2005 |
Depot perphenazine decanoate and enanthate for schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Perphenazine; Schizophrenia | 2000 |
Maintenance antipsychotic drugs do prevent relapse: a reply to Tobias and MacDonald.
Topics: Antipsychotic Agents; Chlorpromazine; Chronic Disease; Drug Evaluation; Fluphenazine; Humans; Perphe | 1976 |
Neuroleptic plasma levels.
Topics: Antipsychotic Agents; Biological Availability; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Pe | 1991 |
The strategy and value of neuroleptic drug monitoring.
Topics: Antipsychotic Agents; Chlorpromazine; Chromatography, Gas; Chromatography, Liquid; Fluphenazine; For | 1985 |
Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects.
Topics: Animals; Antipsychotic Agents; Butyrophenones; Chemical Phenomena; Chemistry; Chlorpromazine; Dibenz | 1974 |
99 trials available for perphenazine and Schizophrenia
| Article | Year |
|---|---|
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Glucose; Haloperidol; Humans; Inflammation; Olanzapine; Perph | 2024 |
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Hospitalization; Humans; Male; Olanzap | 2020 |
Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cocaine-Related Disorders; Comorbidity; Craving; Diagnosi | 2017 |
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.
Topics: Adult; Antipsychotic Agents; Body-Weight Trajectory; Female; Humans; Male; Middle Aged; Olanzapine; | 2019 |
Examination of heterogeneity in treatment response to antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Deprescriptions; Female; Humans; Kaplan-Meier Estimate; Male; Medicatio | 2019 |
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostilit | 2014 |
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Drug Admini | 2014 |
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Dibenzothiazepines; Femal | 2014 |
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi | 2015 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazep | 2016 |
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Dibenzothiazepines; Female; H | 2008 |
Results of phase 3 of the CATIE schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cloza | 2009 |
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Chromosomes, Human, Pair 4; Dibenzothiazepines; Double-Blind | 2011 |
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Emotions; | 2009 |
Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Body Weight; Dose-Response Relationship, | 2010 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; H | 2011 |
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Comorbidity; Depression; Depressive | 2011 |
Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample.
Topics: Analysis of Variance; Antibodies, Viral; Antipsychotic Agents; Cognition Disorders; Double-Blind Met | 2011 |
Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Comorbidity; De | 2011 |
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Awareness; Benzodiazepines; Case-Control Studies; C | 2012 |
Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Double-Blind Method; Dr | 2012 |
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dopamine Antagonists; Double-Bli | 2012 |
A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Perphenazine; Positron-Emission Tomo | 2004 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Buspirone; Denmark; Drug Thera | 2005 |
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bias; Clozapine; Drug Administration Schedule; Episode | 2006 |
Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Haloperidol; Human | 2006 |
Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Femal | 2007 |
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F | 2006 |
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F | 2006 |
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F | 2006 |
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F | 2006 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2007 |
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Cohort Studies; Dibenzothiazepine | 2007 |
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Ethnicity; | 2008 |
Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.
Topics: Antipsychotic Agents; Australia; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Humans; O | 2007 |
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Doub | 2008 |
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.
Topics: Adult; Antipsychotic Agents; Employment; Female; Humans; Interviews as Topic; Male; Middle Aged; Out | 2008 |
What CATIE found: results from the schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dibenzothiaze | 2008 |
[On the question of differences between therapeutic responses after particular neuroleptics in comparison to perphenazine in schizophrenics (author's transl)].
Topics: Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Humans; Perphenazine; Schizophr | 1981 |
Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study.
Topics: Adolescent; Adult; Antipsychotic Agents; Butyrophenones; Chronic Disease; Clinical Trials as Topic; | 1982 |
Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Clopenthixol; Delayed-Action Preparations; D | 1980 |
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Denmark; Double-Blind Method; Female; Humans; Isox | 1993 |
A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Actio | 1994 |
[Efficacy and tolerance of risperidone in various doses (report of a study)].
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Perphenazine; R | 1996 |
Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Female; Flupenthixol; Humans; | 1996 |
Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.
Topics: Adult; Antipsychotic Agents; Clozapine; Cyproheptadine; Female; Humans; Male; Perphenazine; Schizoph | 1996 |
Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Chlorpromazine; Drug Administration S | 1997 |
Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Compulsive Behavior; Female; | 2000 |
Acute antipsychotic drug administration lowers body temperature in drug-free male schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Temperature; Haloperidol; Humans; Longitudinal Studies | 2000 |
Effects of perphenazine enanthate injections on prolactin levels in plasma from schizophrenic women and men.
Topics: Aged; Biperiden; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Perphenazine; Prolacti | 1978 |
Tardive dyskinesia treated with pimozide.
Topics: Aged; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Clinical Trials as Topic; Consciousnes | 1975 |
Phenothiazine-induced ECG abnormalities: effect of a glucose load.
Topics: Adult; Amitriptyline; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Drug Ther | 1977 |
Double-blind comparison of bromperidol and perphenazine.
Topics: Adult; Aged; Behavior; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; M | 1978 |
A controlled clinical trial of amitriptyline added to perphenazine in the treatment of depressed schizophrenics [proceedings].
Topics: Amitriptyline; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Therapy, Combination; | 1979 |
Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amitriptyline; Blood Pressure; Body Weight; Chronic Diseas | 1979 |
[Double-blind comparison of 2 depot neuroleptics (perphenazine enanthate and flupentixol decanoate) in chronic schizophrenia (author's transl)].
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Flupenthixol; Hum | 1979 |
[Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double blind method].
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Clinical | 1976 |
[Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazinedecanoate, fluspirilene, penfluridol, perphenazine-enanthate and pipothiazinepalmitate].
Topics: Administration, Oral; Bipolar Disorder; Catatonia; Clinical Trials as Topic; Delayed-Action Preparat | 1975 |
Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controled study of drug interaction.
Topics: Adult; Age Factors; Ambulatory Care; Amitriptyline; Chlorpromazine; Clinical Trials as Topic; Drug I | 1975 |
The position of trifluoperazine in the group of neuroleptics (a controlled clinical comparative study).
Topics: Adult; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Perphenazine; Schizophrenia; Tri | 1975 |
Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients.
Topics: Administration, Oral; Antipsychotic Agents; Bipolar Disorder; Creatine Kinase; Female; Follow-Up Stu | 1992 |
The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Dose- | 1990 |
[Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
Topics: Adolescent; Adult; Humans; Middle Aged; Perphenazine; Psychotic Disorders; Schizophrenia; Sulpiride | 1990 |
Controlled cross-over comparison of isofloxythepin and perphenazine in the treatment of schizophrenic psychoses.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dibenzothiepins; Double-Blind Method; Female; Humans; | 1989 |
The relationship between perphenazine plasma levels and clinical response in acute schizophrenia.
Topics: Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Huma | 1989 |
Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Meth | 1989 |
Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics.
Topics: Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Depressive Disorder; Double-Blind Me | 1988 |
Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doub | 1985 |
Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dysk | 1985 |
Specific indications for different classes of phenothiazines.
Topics: Adult; Age Factors; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Drug Evaluation; | 1974 |
Effect of antipsychotic drugs on reproductive functions.
Topics: Adult; Butyrophenones; Clinical Trials as Topic; Ejaculation; Humans; Male; Middle Aged; Perphenazin | 1966 |
Clinical studies with propericiazine (R.P. 8909).
Topics: Acute Disease; Adolescent; Adult; Aged; Association; Behavior; Chlorpromazine; Chronic Disease; Clin | 1967 |
Butaperazine (Repoise).
Topics: Chronic Disease; Clinical Trials as Topic; Haloperidol; Humans; Perphenazine; Phenothiazines; Pipera | 1968 |
A comparison of pimozide with perphenazine in the treatment of acute schizophrenic psychoses.
Topics: Acute Disease; Adolescent; Adult; Aged; Benzimidazoles; Butyrophenones; Clinical Trials as Topic; Ev | 1972 |
Intermittent pharmacotherapy in chronic schizophrenia.
Topics: Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Costs and Cost Analysis; Hospitals, Veter | 1973 |
Comparison of the short-term therapeutic effect of oxyprothepine and perphenazine in schizophrenic patients. A controlled study.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Depressive Disorder, Major; Dibenzothiepins; Huma | 1973 |
A controlled comparison of oxypertine and perphenazine in schizophrenic psychoses.
Topics: Adolescent; Adult; Bipolar Disorder; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Indo | 1974 |
An attempt to classify neuroleptic drugs on the basis of short-term clinical comparative studies.
Topics: Basal Ganglia Diseases; Clinical Trials as Topic; Drug Evaluation; Humans; Perphenazine; Schizophren | 1974 |
A double-blind trial of amitriptyline/perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics.
Topics: Adult; Affect; Amitriptyline; Analysis of Variance; Body Weight; Chronic Disease; Clinical Trials as | 1967 |
Penicillamine and schizophrenia--a clinical trial.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle | 1969 |
[Clinical comparison of methophenazine and perphenazine in schizophrenia. A controlled study. Effects on the photomyoclonic threshold].
Topics: Clinical Trials as Topic; Female; Humans; Light; Myoclonus; Paranoid Disorders; Perphenazine; Schizo | 1967 |
[Comparison of triperidol with perphenazine in schizophrenic psychoses. Effect on the photomyoclonic threshold].
Topics: Adolescent; Adult; Antidepressive Agents; Butyrophenones; Clinical Trials as Topic; Depressive Disor | 1970 |
[Controlled comparative study of methylperidol and perphenazine in schizoprenic psychoses].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Butyrophenones; Clinical Trials as Topic; Female; Fl | 1970 |
[Controlled studies with thiothixene and perphenazine in schizophrenic psychoses].
Topics: Adult; Affective Symptoms; Clinical Trials as Topic; Depressive Disorder, Major; Female; Humans; Mal | 1970 |
Double blind study of clopenthixol and chlorpromazine in acute hospitalized schizophrenics.
Topics: Acute Disease; Adolescent; Adult; Aged; Aspartate Aminotransferases; Blood Pressure; Body Weight; Ch | 1970 |
A controlled trial of combined medications on behavioral and extrapyramidal effects.
Topics: Adult; Aged; Amitriptyline; Analysis of Variance; Clinical Trials as Topic; Extrapyramidal Tracts; H | 1970 |
Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia.
Topics: Adult; Aged; Amitriptyline; Chronic Disease; Clinical Trials as Topic; Female; Humans; Middle Aged; | 1970 |
Combination medications in psychiatric treatment: patterns in a group of elderly hospital patients.
Topics: Age Factors; Aged; Amitriptyline; Antidepressive Agents; Antihypertensive Agents; Antisocial Persona | 1971 |
Comparison of the therapeutic results of clothiapin and perphenazine in schizophrenia.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Catatonia; Clinical Trials as Topic; Dibenzothiazepines; | 1971 |
A double blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy.
Topics: Age Factors; Chronic Disease; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Hospita | 1971 |
Competing voice messages. Effects of message load and drugs on the ability of acute schizophrenics to attend.
Topics: Adolescent; Adult; Attention; Chlorpromazine; Female; Humans; Middle Aged; Pentobarbital; Perphenazi | 1967 |
The effect of a protriptyline-perphenazine combination in chronic psychiatric patients.
Topics: Adolescent; Adult; Amitriptyline; Clinical Trials as Topic; Depression; Female; Humans; Intellectual | 1966 |
A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population.
Topics: Adult; Animals; Clopenthixol; Humans; Male; Middle Aged; Perphenazine; Piperazines; Schizophrenia; T | 1968 |
Protrptyline in the treatment of chronic schizophrenic patients.
Topics: Adolescent; Adult; Clinical Trials as Topic; Desipramine; Dibenzocycloheptenes; Female; Humans; Male | 1970 |
Triavil and Etrafon.
Topics: Amitriptyline; Chlordiazepoxide; Clinical Trials as Topic; Depression; Diazepam; Female; Humans; Mep | 1966 |
Perphenazine-amitriptyline in the treatment of schizophrenia.
Topics: Amitriptyline; Clinical Trials as Topic; Female; Humans; Perphenazine; Placebos; Schizophrenia | 1966 |
Clinical evaluation of neuroleptic drug action, particularly considering butyrophenones.
Topics: Aged; Butyrophenones; Chlorpromazine; Clinical Trials as Topic; Electrocardiography; Female; Haloper | 1966 |
Current status of pharmacotherapy in schizophrenia.
Topics: Adult; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Humans; Methotrimeprazine; Middle | 1966 |
Comparison of the therapeutic effect of flupenthixol and perphenazine in schizophrenia.
Topics: Adolescent; Adult; Ethanol; Female; Humans; Male; Middle Aged; Movement Disorders; Perphenazine; Pip | 1970 |
[Depot-neuroleptics in the treatment of schizophrenia].
Topics: Adult; Chlorpromazine; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Middl | 1971 |
185 other studies available for perphenazine and Schizophrenia
| Article | Year |
|---|---|
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphe | 2008 |
Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Olanzapine; Perphenazine; Recurrence; Ris | 2022 |
Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Female; Finland; Flupenthixol; Follow-Up Studies; Huma | 2018 |
Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biomarkers; Clozapine; Humans; Middle Aged; Oxidative | 2018 |
Lamotrigine Cross-Reactivity With Phencyclidine in Rapid Urine Toxicology in a Research Study.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; False Positive Reactions; Female; Humans; Imm | 2018 |
Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.
Topics: Adult; Antipsychotic Agents; Black or African American; Clinical Trials as Topic; Female; Hispanic o | 2013 |
Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report.
Topics: Actigraphy; Antipsychotic Agents; Brain; Brain Waves; Cognition; Drug Substitution; Humans; Magnetic | 2013 |
Schizophrenia research: where are we?
Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Family; Humans; Medication Adherence; Nonverbal | 2014 |
Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.
Topics: Adult; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Female | 2014 |
Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.
Topics: Adult; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Female | 2014 |
Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.
Topics: Adult; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Female | 2014 |
Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data.
Topics: Adult; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Female | 2014 |
Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study.
Topics: Adult; Alkaline Phosphatase; Antipsychotic Agents; Aripiprazole; Bone Density; Chlorpromazine; Cloza | 2014 |
Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics.
Topics: Adult; Amino Acids; Antipsychotic Agents; Chromatography, Ion Exchange; Clopenthixol; Clozapine; Coh | 2015 |
Clinical experiences and clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine | 2008 |
BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
Topics: Acetylcholine; Amphetamine; Animals; Antipsychotic Agents; Biological Availability; Brain; Catalepsy | 2009 |
Revisiting the CATIE schizophrenia study. Although questions remain, some clinical guidance has emerged.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Health Planning Guidelines; Humans; Perphenazine; Sc | 2008 |
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Topics: Adult; Age Distribution; Aged; Antipsychotic Agents; Case-Control Studies; Cause of Death; Clozapine | 2009 |
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Topics: Adult; Age Distribution; Aged; Antipsychotic Agents; Case-Control Studies; Cause of Death; Clozapine | 2009 |
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Topics: Adult; Age Distribution; Aged; Antipsychotic Agents; Case-Control Studies; Cause of Death; Clozapine | 2009 |
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Topics: Adult; Age Distribution; Aged; Antipsychotic Agents; Case-Control Studies; Cause of Death; Clozapine | 2009 |
Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Female; Finland; Haloperidol; Humans; Ma | 2010 |
The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs.
Topics: Antipsychotic Agents; Benzodiazepines; Epidemiologic Research Design; Geography; Humans; National In | 2010 |
Schizophrenia: The drug deadlock.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cognition; Dopamine D2 Receptor | 2010 |
Alternative methods for testing treatment effects on the basis of multiple outcomes: simulation and case study.
Topics: Antipsychotic Agents; Biostatistics; Clinical Trials as Topic; Dibenzothiazepines; Humans; Likelihoo | 2011 |
The NIMH-CATIE Schizophrenia Study: what did we learn?
Topics: Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Drug Substitution; Humans; | 2011 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperido | 2011 |
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Attention; Benzodiazepines; Dibenzot | 2012 |
Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Drug Prescriptions; Female; Hospita | 2012 |
[Initial results in the treatment of chronic mental disorders with perphenazine (Trilafon). Therapeutic and psychopathological research].
Topics: Mental Disorders; Perphenazine; Psychopathology; Research; Schizophrenia | 1960 |
[Results of treatment with perphenazine in schizophrenic psychoses with reference to extrapyramidal symptomatology].
Topics: Extrapyramidal Tracts; Mental Disorders; Perphenazine; Psychotic Disorders; Schizophrenia | 1961 |
Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital.
Topics: Antipsychotic Agents; Chlorpromazine; Perphenazine; Phenobarbital; Phenothiazines; Prochlorperazine; | 1960 |
The use of a phenothiazine compound in the rehabilitation of schizophrenic patients.
Topics: Humans; Medicine; Perphenazine; Phenothiazines; Schizophrenia | 1962 |
Protein-bound iodine in patients receiving perphenazine.
Topics: Humans; Iodine; Mental Disorders; Perphenazine; Psychotic Disorders; Schizophrenia; Thyroid Function | 1963 |
[On the use of etaperazine in the treatment of schizophrenia].
Topics: Humans; Perphenazine; Schizophrenia | 1963 |
[A neuroleptic derivative of phenothiazine: perphenazine].
Topics: Alcoholism; Antipsychotic Agents; Character; Delusions; Dementia; Humans; Perphenazine; Phenothiazin | 1963 |
Withdrawal of perphenazine in chronic schizophrenia.
Topics: Conduct Disorder; Humans; Perphenazine; Schizophrenia | 1963 |
[Study of the effects of perphenazine upon EEG and minor tremor in schizophrenics by means of automatic frequency analyser].
Topics: Electroencephalography; Perphenazine; Schizophrenia; Tremor | 1961 |
Iodoamino acid distribution in the serum of schizophrenic patients receiving perphenazine.
Topics: Amino Acids; Humans; Iodine; Perphenazine; Schizophrenia; Thyroid Function Tests; Thyroid Hormones | 1963 |
Amitriptyline-perphenazine in the treatment of schizophrenia.
Topics: Amitriptyline; Antidepressive Agents; Drug Combinations; Humans; Perphenazine; Schizophrenia | 1963 |
EVALUATION OF COMBINED ANTIDEPRESSANT AND TRANQUILIZINGDRUG (AMITRIPTYLINE-PERPHENAZINE) IN THE TREATMENT OF HOSPITALIZED CHRONIC SCHIZOPHRENICPATIENTS.
Topics: Amitriptyline; Antidepressive Agents; Drug Combinations; Humans; Perphenazine; Psychological Tests; | 1963 |
THE MEASUREMENT OF ACTIVITY PATTERNS OF SCHIZOPHRENIC PATIENTS.
Topics: Chlorpromazine; Humans; Imipramine; Perphenazine; Phenelzine; Placebos; Reserpine; Schizophrenia; Tr | 1963 |
PERPHENAZINE AND THYROID FUNCTION.
Topics: Humans; Perphenazine; Schizophrenia; Thyroid Function Tests; Thyroid Gland | 1963 |
ANXIETY AND DEPRESSION: TREATMENT IN GENERAL PRACTICE.
Topics: Amitriptyline; Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Family Practice; Female; | 1963 |
PHENOTHIAZINE-PRODUCED EXTRA-PYRAMIDAL SYSTEM DISTURBANCE.
Topics: Behavior; Central Nervous System Diseases; Extrapyramidal Tracts; Humans; Motor Skills; Perphenazine | 1964 |
PERPHENAZINE COMBINED WITH AMITRYPTILINE IN NEWLY ADMITTED SCHIZOPHRENICS.
Topics: Amitriptyline; Hospitalization; Humans; Perphenazine; Schizophrenia; Toxicology | 1963 |
PREDRUG BEHAVIOR AS A PREDICTOR OF RESPONSE TO PHENOTHIAZINES AMONG SCHIZOPHRENICS.
Topics: Antipsychotic Agents; Chlorpromazine; Humans; Perphenazine; Phenobarbital; Phenothiazines; Prochlorp | 1963 |
EEG AND BEHAVIORAL CHANGES IN SCHIZOPHRENIA.
Topics: Antidepressive Agents; Behavior; Chlorpromazine; Deanol; Electroencephalography; Humans; Perphenazin | 1964 |
[PHARMACOTHERAPY OF SCHIZOPHRENIA. I. PHARMACOTHERAPY WITH IN-PATIENTS OF SHORT-TERM ADMISSION].
Topics: Adolescent; Catatonia; Child; Chlorpromazine; Convulsive Therapy; Electroconvulsive Therapy; Humans; | 1964 |
THE USE OF PERPHENAZINE IN THE TREATMENT OF DRUG RESISTANT SCHIZOPHRENICS.
Topics: Perphenazine; Schizophrenia; Toxicology | 1964 |
PIGMENTARY RETINOPATHY ASSOCIATED WITH THIORIDAZINE: REPORT OF A CASE WITH A MAXIMUM DAILY DOSE OF 1400 MGM.
Topics: Aged; Humans; Parasympatholytics; Perphenazine; Retinitis Pigmentosa; Schizophrenia; Thioridazine; T | 1964 |
SYMPTOM SPECIFICITY OF ANTI-PSYCHOTIC DRUGS.
Topics: Chlorpromazine; Humans; Mental Disorders; Perphenazine; Psychopharmacology; Psychotic Disorders; Sch | 1964 |
COMPARISON OF BUTAPERAZINE AND PERPHENAZINE: A DOUBLE-BLIND CONTROLLED STUDY.
Topics: Biomedical Research; Double-Blind Method; Humans; Intellectual Disability; Neurotic Disorders; Paran | 1964 |
[FAMILY ORIENTED PSYCHOTHERAPY FOR A SCHIZOPHRENIC].
Topics: Family; Humans; Parent-Child Relations; Perphenazine; Psychotherapy; Reserpine; Schizophrenia; Socia | 1964 |
DRUG MAINTENANCE PROBLEMS OF REHABILITATED MENTAL PATIENTS: THE CURRENT DRUG DOSAGE "MERRY-GO-ROUND".
Topics: Chlordiazepoxide; Chlorpromazine; Depression; Imipramine; Mental Disorders; Mentally Ill Persons; Pe | 1964 |
PERPHENAZINE (TRILAFON) METABOLISM IN PSYCHOTIC PATIENTS.
Topics: Chlorpromazine; Chromatography; Humans; Mental Disorders; Metabolism; Perphenazine; Psychotic Disord | 1964 |
[DYNAMIC STUDIES ON DRAWING IN THE COURSE OF TREATMENT WITH PSYCHOTROPIC AGENTS].
Topics: Antisocial Personality Disorder; Bipolar Disorder; Depressive Disorder, Major; Imipramine; Mental Di | 1964 |
TRANQUILIZERS AND SUICIDE IN THE SCHIZOPHRENIC PATIENT.
Topics: Aging; Alcoholism; Biomedical Research; Chlorpromazine; Drug Therapy; Marriage; Perphenazine; Prochl | 1964 |
MANAGEMENT OF THE EMOTIONALLY ILL CHILD. LONG-TERM TRIALS WITH A NEW AGENT.
Topics: Adolescent; Antidepressive Agents; Brain; Brain Damage, Chronic; Child; Child Behavior Disorders; Dr | 1964 |
FURTHER REPORT ON PROTEIN-BOUND IODINE IN PATIENTS RECEIVING PERPHENAZINE.
Topics: Biomedical Research; Diagnosis, Differential; Hyperthyroidism; Iodine; Perphenazine; Pharmacology; S | 1964 |
[CLINICAL EXPERIENCES WITH A NEW ANTIPARKINSON AGENT, AKINETON, WITH SPECIAL REFERENCE TO EXTRAPYRAMIDAL SYMPTOMS CAUSED BY PHENOTHIAZINE DERIVATIVES].
Topics: Adolescent; Antiparkinson Agents; Biperiden; Central Nervous System Diseases; Child; Chlorpromazine; | 1964 |
SENSORY CHANGES WITH PHENOTHIAZINE MEDICATION IN SCHIZOPHRENIC PATIENTS.
Topics: Biomedical Research; Chlorpromazine; Drug Therapy; Figural Aftereffect; Flicker Fusion; Form Percept | 1964 |
CHANGES IN SERUM PROTEINS AND CEREBROSPINAL FLUID PROTEINS DURING PHARMACOTHERAPY OF PSYCHOSES.
Topics: Alcoholism; Bipolar Disorder; Blood Proteins; Cerebrospinal Fluid Proteins; Chlorpromazine; Drug The | 1964 |
[WITHDRAWAL OF PSYCHOPHARMACA AND RELAPSE IN SCHIZOPHRENICS].
Topics: Chlorprothixene; Chronic Disease; Humans; Paranoid Disorders; Perphenazine; Recurrence; Schizophreni | 1964 |
[RETINAL DAMAGE AFTER TREATMENT WITH CHLORPROTHIXENE].
Topics: Chlorpromazine; Chlorprothixene; Drug Therapy; Perphenazine; Retinitis; Schizophrenia; Thioridazine; | 1964 |
THE NEUROPSYCHIATRIC COMPLICATIONS OF VIRAL HEPATITIS.
Topics: Central Nervous System Diseases; Drug Therapy; Hepatitis A; Humans; Mental Disorders; Ohio; Perphena | 1965 |
[USE OF ETAPERAZINE IN RESISTANT TO THERAPY SCHIZOPHRENIC PATIENTS].
Topics: Drug Therapy; Humans; Perphenazine; Schizophrenia | 1964 |
A LONG-TERM STUDY OF 12 HOSPITALIZED PSYCHIATRIC PATIENTS TREATED WITH PERPHENAZINE.
Topics: Drug Therapy; Geriatrics; Humans; Longitudinal Studies; Mental Disorders; Paresis; Perphenazine; Psy | 1965 |
PRODUCTIVITY OF CHRONIC SCHIZOPHRENICS IN A SHELTERED WORKSHOP: A QUANTITATIVE EVALUATION OF THE EFFECTS OF DRUG THERAPY.
Topics: Biomedical Research; Drug Therapy; Humans; Occupational Therapy; Perphenazine; Phenelzine; Placebos; | 1965 |
PENTOTHAL INDUCED CHANGES IN EEG AS A PROGNOSTIC INDEX IN DRUGS THERAPY OF PSYCHOTIC PATIENTS.
Topics: Chlorpromazine; Depression; Drug Therapy; Electroencephalography; Mental Disorders; Neurotic Disorde | 1965 |
TIME-SERIES, FREQUENCY ANALYSIS, AND ELECTROGENESIS OF THE EEGS OF NORMALS AND PSYCHOTICS BEFORE AND AFTER DRUGS.
Topics: Amphetamine; Antidepressive Agents; Barbiturates; Biomedical Research; Caffeine; Central Nervous Sys | 1965 |
SKIN PIGMENTATION, A RARE SIDE EFFECT OF CHLORPROMAZINE.
Topics: Chemical Phenomena; Chemistry; Chlorpromazine; Diagnosis, Differential; Drug Therapy; Epilepsy; Eye | 1965 |
ETRAFON IN REGRESSED SCHIZOPHRENIC PATIENTS.
Topics: Amitriptyline; Biomedical Research; Drug Therapy; Perphenazine; Placebos; Schizophrenia; Toxicology | 1965 |
PHENOTHIAZINE REDUCTION AS A CAUSE OF REHOSPITALIZATION.
Topics: Chlorpromazine; Drug Therapy; Fluphenazine; Hospitalization; Humans; Perphenazine; Phenothiazines; P | 1965 |
[STUDY OF MODIFICATIONS OF STEREOMORPHISMS OF A SCHIZOPHRENIC PATIENT BY MEANS OF PSYCHOPHARMACOLOGIC DRUGS].
Topics: Antidepressive Agents; Art; Hallucinogens; Humans; Lysergic Acid Diethylamide; Perphenazine; Psilocy | 1964 |
[EXPERIENCES WITH FRENOLONE IN PSYCHIATRY].
Topics: Benzoates; Humans; Perphenazine; Phenothiazines; Psychiatry; Schizophrenia | 1965 |
TWO-YEAR FOLLOW-UP STUDY OF PROTEIN-BOUND IODINE ELEVATION IN PATIENTS RECEIVING PERPHENAZINE.
Topics: Biomedical Research; Drug Therapy; Follow-Up Studies; Iodine; Mental Disorders; Perphenazine; Phenel | 1965 |
COMPUTER ANALYSIS OF DRUG EFFECTS ON THE ELECTROENCEPHALOGRAMS OF NORMAL AND PSYCHOTIC SUBJECTS.
Topics: Antidepressive Agents; Biomedical Research; Chlorpromazine; Computers; Drug Therapy; Electroencephal | 1964 |
Perphenazine (fentazin) in the management of chronic schizophrenia.
Topics: Disease Management; Perphenazine; Schizophrenia | 1960 |
[Perphenazine in the treatment of schizophrenia with special reference to extrapyramidal symptomatology].
Topics: Humans; Perphenazine; Schizophrenia | 1961 |
Schizophrenia, VI: Treatments.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Perphenazi | 2003 |
The CATIE schizophrenia effectiveness trial.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Drug Administra | 2005 |
Interpreting the results of the CATIE study.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; National Institute of Mental Health (U.S.); Perphe | 2006 |
Interpreting the results of the CATIE study.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Ri | 2006 |
Interpreting the results of the CATIE study.
Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Ri | 2006 |
Antipsychotic drugs and schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; P | 2006 |
Antipsychotic drugs and schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Developing Countries; Health Policy; H | 2006 |
Selecting antipsychotics in schizophrenia: lessons from CATIE.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clinical Trials, Phase I as Topic; Dose-Respon | 2006 |
Cost-effectiveness of schizophrenia pharmacotherapy.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Drug Costs; Humans; Perphenazine; Randomized Controlled | 2007 |
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dose- | 2007 |
Aripiprazole and perphenazine: no difference.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Marketing; Perphenazine; Piperazines; Quality of Life; Q | 2007 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Hum | 2008 |
Introduction to the CATIE special section.
Topics: Antipsychotic Agents; Body Weight; Clinical Trials as Topic; Clozapine; Cognition; Health Policy; Hu | 2008 |
Perphenazine therapy among outpatients.
Topics: Bipolar Disorder; Brain Damage, Chronic; Depressive Disorder, Major; Female; Humans; Intellectual Di | 1967 |
[Dynamics of integral parameters of the background EEG during treatment with neuroleptics].
Topics: Antipsychotic Agents; Automatism; Brain; Chlorpromazine; Clozapine; Electroencephalography; Haloperi | 1982 |
Low serum neuroleptic levels predict relapse in schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Male; Middle A | 1982 |
[Ataractic treatment in psychiatry and general medicine. Overview of preparations, 2].
Topics: Bromazepam; Carbamazepine; Chlordiazepoxide; Chlorpromazine; Humans; Perphenazine; Psychophysiologic | 1983 |
With onions and tears: a multidimensional analysis of a counter-ritual.
Topics: Adult; Affect; Crying; Denial, Psychological; Family; Family Therapy; Female; Humans; Laughter; Male | 1981 |
Schizophrenia therapy: the trigger effect. An exceptional response to a short intervention.
Topics: Adult; Humans; Male; Perphenazine; Physician-Patient Relations; Psychotherapy, Brief; Schizophrenia; | 1980 |
Delirium: an SSRI-benztropine adverse effect?
Topics: Adult; Age Factors; Aged; Benztropine; Delirium; Drug Interactions; Fluoxetine; Humans; Middle Aged; | 1995 |
[Changes in the world view of schizophrenic patients].
Topics: Adult; Delusions; Dominance, Cerebral; Humans; Magic; Male; Perphenazine; Schizophrenia; Schizophren | 1993 |
Carbamazepine interference in a high-performance liquid chromatography analysis for perphenazine.
Topics: Adult; Carbamazepine; Chromatography, High Pressure Liquid; Humans; Male; Perphenazine; Schizophreni | 1994 |
Platelet monoamine oxidase activity in neuroleptic-naive schizophrenic patients: lack of influence of chronic perphenazine treatment.
Topics: Adult; Blood Platelets; Female; Humans; Male; Monoamine Oxidase; Perphenazine; Psychiatric Status Ra | 1994 |
Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Clopenthixol; Delayed-Action Preparations; Dyski | 1996 |
Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Dipeptidy | 1996 |
Large variations of plasma levels during maintenance treatment with depot neuroleptics.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Drug Monitoring; Female; Flupenthixo | 1996 |
Dopamine D2-receptor density in humans as assessed with SPET and the new high-affinity ligand 123I-NCQ298: a pilot study.
Topics: Adult; Aged; Antipsychotic Agents; Brain; Cerebrovascular Circulation; Dopamine Agonists; Female; Ha | 1998 |
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Female; Galactorrhea; Humans; Hyperprolact | 1998 |
[Atypical acute dystonia].
Topics: Acute Disease; Adult; Antipsychotic Agents; Aphonia; Dyskinesia, Drug-Induced; Dystonia; Humans; Mal | 1998 |
A dilemma born of progress: switching from clozapine to a newer antipsychotic.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Clozapine; Drug Monitoring; Humans | 1999 |
Acquired aplastic anemia secondary to perphenazine.
Topics: Adult; Anemia, Aplastic; Antipsychotic Agents; Blood Cell Count; Bone Marrow; Humans; Male; Perphena | 1999 |
Propranolol: a treatment for pseudoakathisia.
Topics: Adult; Agnosia; Akathisia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Perphenazine; Propr | 1994 |
Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses.
Topics: Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Chi-Square Distribution; Cl | 2001 |
The changes of biological markers and treatment efficacy in schizophrenia.
Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Biomarkers; Brain; Cognition; Dexamethasone | 2001 |
Agranulocytosis and neutropenia with typical and atypical neuroleptics.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Leukocyte | 2001 |
High-dosage and versatile drug therapy with treatment-resistant psychotic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Doxepin; Female; Hospitals, Psychiatric; Hu | 1976 |
Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Drug Therapy, Combination | 1979 |
Dopaminergic factors in human prolactin regulation: a pituitary model for the study of a neuroendocrine system in man.
Topics: Adult; Dopamine; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Neurosecretory Systems | 1979 |
Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency.
Topics: Chlorpromazine; Dopamine; Dose-Response Relationship, Drug; Fluphenazine; Haloperidol; Humans; Male; | 1977 |
[Prolonged action neuroleptics (review of the foreign literature)].
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Child; Chronic Diseas | 1975 |
Metabolic interaction between amitriptyline and perphenazine in psychiatric patients.
Topics: Adult; Amitriptyline; Drug Interactions; Female; Humans; Male; Middle Aged; Nortriptyline; Perphenaz | 1979 |
Increase in weight after treatment with depot neuroleptics.
Topics: Administration, Oral; Body Weight; Clopenthixol; Delayed-Action Preparations; Drug Implants; Female; | 1979 |
[A comparative study of the longacting neuroleptics perphenazin-enanthate and fluspirilene (author's transl)].
Topics: Chronic Disease; Delayed-Action Preparations; Fluspirilene; Humans; Perphenazine; Psychiatric Status | 1979 |
Gas chromatographic determination of amitriptyline, nortriptyline and perphenazine in plasma of schizophrenic patients after administration of the combination of amitriptyline with perphenazine.
Topics: Adult; Amitriptyline; Chromatography, Gas; Drug Combinations; Female; Humans; Male; Middle Aged; Nor | 1979 |
Perphenazine-induced systemic lupus erythematosus-like syndrome.
Topics: Adult; Female; Humans; Lupus Erythematosus, Systemic; Perphenazine; Schizophrenia | 1978 |
Thrombocytopenia in the absence of leukopenia associated with the use of neuroleptics.
Topics: Adult; Benztropine; Chlorpromazine; Haloperidol; Humans; Male; Perphenazine; Schizophrenia; Thalasse | 1978 |
Drug-induced dystonia.
Topics: Adjustment Disorders; Adult; Basal Ganglia Diseases; Chlorpromazine; Chlorprothixene; Female; Fluphe | 1975 |
Effects of phenothiazines and social skills training in a withdrawn schizophrenic.
Topics: Adult; Behavior Therapy; Benztropine; Chlorpromazine; Feedback; Follow-Up Studies; Generalization, P | 1975 |
Effects of perphenazine on imipramine metabolism in man.
Topics: Adult; Desipramine; Drug Interactions; Female; Glucuronates; Humans; Imipramine; Male; Middle Aged; | 1975 |
[Frequency of sex chromatin among mental patients].
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Chlorpromazine; Chromosome Aberrations; Chromosome Disord | 1992 |
Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
Topics: Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Lithium | 1992 |
Cycloid psychosis: regional cerebral blood flow correlates of a psychotic episode.
Topics: Adult; Aged; Bipolar Disorder; Blood Flow Velocity; Cerebral Cortex; Chlorpromazine; Dominance, Cere | 1992 |
Drug-responsive symptoms during early neuroleptic treatment.
Topics: Adult; Benztropine; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Th | 1992 |
Acute pulmonary edema induced by overdosage of phenothiazines.
Topics: Acute Disease; Adult; Chlorpromazine; Drug Overdose; Female; Humans; Lung; Male; Middle Aged; Perphe | 1992 |
Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.
Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Female; Flupenthixol; Humans; Male; Middle | 1991 |
Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients.
Topics: Acute Disease; Adult; Aged; Basal Ganglia Diseases; Female; Handwriting; Humans; Male; Middle Aged; | 1991 |
Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans.
Topics: Administration, Oral; Adult; Clopenthixol; Debrisoquin; Female; Humans; Hydroxylation; Male; Perphen | 1991 |
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Chromatography, High Pressure Liquid; Depressive | 1991 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
[Gene localization might make it possible to prevent schizophrenia].
Topics: Adult; Chromosome Aberrations; Chromosomes, Human, Pair 5; Female; Gene Frequency; Humans; Methotrim | 1990 |
A consumer's report. Psychiatric survival. Case record of Angela Fazio.
Topics: Dystonia; Female; Hallucinations; Humans; Lithium; Loxapine; Orthomolecular Therapy; Perphenazine; P | 1990 |
Cross-over comparison of the therapeutic effects of sulpiride and perphenazine in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Perphenazine; S | 1989 |
Intraindividual comparison of the effect of perphenazine and of the combination of perphenazine and lithium in schizophrenia.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hu | 1989 |
Controlled cross-over comparison of carbamazepine with perphenazine in schizophrenic psychoses.
Topics: Adult; Antipsychotic Agents; Carbamazepine; Female; Humans; Male; Middle Aged; Mood Disorders; Perph | 1989 |
Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
Topics: Administration, Oral; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response | 1985 |
Idiosyncratic neuroleptic response.
Topics: Adult; Antipsychotic Agents; Female; Humans; Perphenazine; Schizophrenia; Schizophrenic Psychology | 1987 |
Lithium-responsive schizophrenia and rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Lithium; Lithium Carbonate; | 1988 |
Perphenazine decanoate in sesame oil vs. perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications.
Topics: Adult; Delayed-Action Preparations; Female; Humans; Kinetics; Male; Middle Aged; Perphenazine; Pharm | 1985 |
Pharmacokinetic implications of different oil vehicles used in depot neuroleptic treatment.
Topics: Adult; Delayed-Action Preparations; Humans; Injections, Intramuscular; Kinetics; Male; Perphenazine; | 1985 |
Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Pa | 1985 |
Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
Topics: Adult; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1985 |
Systemic lupus erythematosus induced by psychotropic drugs.
Topics: Adult; Blood Cell Count; Chlorpromazine; Chlorprothixene; Female; Humans; Lupus Erythematosus, Syste | 1971 |
Clinical differences among phenothiazines in schizophrenics. Introduction: specific indications for antipsychotics: elusive end of the rainbow.
Topics: Antipsychotic Agents; Depression; Haloperidol; Humans; Kinetics; Perphenazine; Phenothiazines; Piper | 1974 |
[Sudden cessation of psychotropic drugs].
Topics: Adolescent; Adult; Amitriptyline; Antidepressive Agents; Bipolar Disorder; Blood Pressure; Chlorprom | 1974 |
Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Binding, Competitive; Brain; Chlorpromazine; | 1974 |
The effect of phenothiazines on cerebrospinal fluid.
Topics: Cerebrospinal Fluid Proteins; Chlorpromazine; gamma-Globulins; Humans; Perphenazine; Schizophrenia; | 1966 |
Serum protein-bound iodine and serum thyroxine during perphenazine therapy.
Topics: Adolescent; Adult; Aged; Chemistry, Clinical; Humans; Iodine Radioisotopes; Male; Middle Aged; Perph | 1967 |
[Hallucinatory paraphrenic syndrome in the course of schizophrenia].
Topics: Adult; Automatism; Azo Compounds; Delirium; Hallucinations; Haloperidol; Humans; Illusions; Paranoid | 1967 |
[Neuroleptic therapy of schizophrenia from pharmacological viewpoint].
Topics: Animals; Apomorphine; Arousal; Caudate Nucleus; Chlorpromazine; Chlorprothixene; Electroencephalogra | 1969 |
Conditions in adolescents who were borderline psychotics as children. Three cases illustrating diagnostic and therapeutic problems.
Topics: Adolescent; Adolescent Psychiatry; Child Development; Diagnosis, Differential; Ethanol; Female; Hosp | 1973 |
Maintenance neuroleptic treatment: an epidemiological study.
Topics: Czechoslovakia; Humans; Methotrimeprazine; Perphenazine; Schizophrenia; Thioridazine | 1973 |
A blind comparison of clozapine and perphenazine in schizophrenics.
Topics: Adult; Catatonia; Dibenzothiepins; Female; Humans; Male; Perphenazine; Schizophrenia; Schizophrenia, | 1973 |
Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.
Topics: Animals; Antidepressive Agents; Carbon Radioisotopes; Chlordiazepoxide; Diazepam; Dose-Response Rela | 1974 |
Clinical studies with clopenthixol (sordinol) on chronic psychiatric patients.
Topics: Chlorprothixene; Clopenthixol; Female; Humans; Male; Perphenazine; Schizophrenia; Tranquilizing Agen | 1966 |
Perphenazine and serum protein bound iodine.
Topics: Autoradiography; Blood Proteins; Chromatography; Drug Contamination; Electrophoresis; Follow-Up Stud | 1968 |
The electrophoretic pattern of alkaline phosphatase in schizophrenic females under long-term treatment with neuroleptic drugs and in young and old healthy women.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Blood Protein Electrophoresis; Chlorpromazine; Chlor | 1969 |
Withdrawal symptoms after long-term treatment with neuroleptics.
Topics: Adult; Aged; Blood Circulation; Chlorpromazine; Fever; Humans; Hyperkinesis; Hypotension; Hypothermi | 1972 |
The rabbit syndrome. A peculiar extrapyramidal reaction.
Topics: Aged; Anxiety; Basal Ganglia Diseases; Benztropine; Chlorpromazine; Fatigue; Female; Humans; Male; M | 1972 |
Reversal of benztropine toxicity by physostigmine.
Topics: Brain; Chlorpromazine; Female; Humans; Imipramine; Memory, Short-Term; Parasympatholytics; Perphenaz | 1972 |
[Follow-up studies of schizophrenia].
Topics: Adult; Catalepsy; Catatonia; Chlorpromazine; Chronic Disease; Convulsive Therapy; Depersonalization; | 1971 |
[Pharmacologic combinations in the therapy of depression: experiences with Mutabon (perphenazine and amitriptyline)].
Topics: Adult; Amitriptyline; Analysis of Variance; Depression; Drug Combinations; Evaluation Studies as Top | 1971 |
[Treatment of schizophrenics with perphenazine enanthate].
Topics: Adolescent; Adult; Aged; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Perphenazin | 1971 |
[Chronic schizophrenia treated with depot perphenazine].
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male | 1971 |
[Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
Topics: Adolescent; Adult; Aged; Butyrophenones; Chlorpromazine; Dementia; Depressive Disorder, Major; Dysau | 1969 |
[Comparison of the therapeutic effect of triperidol with perphenazine in schizophrenia].
Topics: Adolescent; Adult; Antidepressive Agents; Butyrophenones; Female; Fluorine; Humans; Male; Middle Age | 1969 |
Action of L-Dopa in drug induced extrapyramidalism.
Topics: Adult; Chlorpromazine; Chronic Disease; Dihydroxyphenylalanine; Extrapyramidal Tracts; Female; Human | 1970 |
The effects of phenothiazine therapy on lymphocyte transformation in schizophrenia.
Topics: Adult; Female; Humans; Lectins; Lymphocyte Activation; Lymphocytes; Male; Middle Aged; Perphenazine; | 1970 |
Further clinical experience with octoclothepin.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Dibenzothiepins; Female; Humans; Male; Middle Aged; Parki | 1970 |
[Perphenazine enanthate in the treatment of chronic schizophrenia].
Topics: Adult; Chronic Disease; Female; Humans; Male; Perphenazine; Schizophrenia | 1970 |
Treatment of psychic masochism in schizophrenic patients.
Topics: Adolescent; Adult; Amitriptyline; Behavior Therapy; Chlordiazepoxide; Diazepam; Female; Haloperidol; | 1970 |
Sudden death in phenothiazine therapy. (A clinicopathologic study of 12 cases).
Topics: Adolescent; Adult; Aged; Asphyxia; Autopsy; Brain; Brain Diseases; Chlorpromazine; Death, Sudden; Dr | 1970 |
Interaction measurements in psychiatric patients with early total deafness.
Topics: Adolescent; Adult; Aged; Chlorpromazine; Communication; Deafness; Female; Humans; Interpersonal Rela | 1967 |
Factors affecting an influence of blood plasma from schizophrenics on an action of 3,4-dimethoxyphenylethylamine.
Topics: Animals; Calcium; Central Nervous System; Crowding; Drug Antagonism; Drug Synergism; Humans; Mice; M | 1968 |
Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background.
Topics: Acute Disease; Adult; Attention; Auditory Perception; Chlorpromazine; Chronic Disease; Dextroampheta | 1968 |
[On the problem of the general and elective action of psycholeptics in the therapy of schizophrenia].
Topics: Catatonia; Chlordiazepoxide; Chlorpromazine; Haloperidol; Humans; Paranoid Disorders; Perphenazine; | 1968 |
[Isolated oculogyric spasm in clopenthixol and perphenazine therapy].
Topics: Adult; Clopenthixol; Eye Diseases; Female; Humans; Male; Perphenazine; Piperazines; Schizophrenia; S | 1968 |
Single daily doses of neuroleptic drugs.
Topics: Chlorpromazine; Chlorprothixene; Chronic Disease; Dosage Forms; Fluphenazine; Haloperidol; Humans; M | 1969 |
Extrinsic factors influencing responses to psychotherapeutic drugs.
Topics: Adult; Amitriptyline; Analysis of Variance; Black or African American; Chlorpromazine; Depression; D | 1969 |
Use of methylphenidate to counteract acute dystonic effects of phenothiazines.
Topics: Adult; Humans; Male; Methylphenidate; Movement Disorders; Perphenazine; Schizophrenia; Torticollis; | 1966 |
A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Haloperidol; Humans; Middle Aged; Orphenadrine; Parasympatholytic | 1966 |
Combined use of an anti-depressant with tranquilizer in the management of depression.
Topics: Amitriptyline; Anxiety; Bipolar Disorder; Depression; Drug Synergism; Electroconvulsive Therapy; Hum | 1966 |